Consensus on control of risky nonvariceal upper gastrointestinal bleeding in Taiwan with National Health Insurance

Bor-Shyang Sheu, Chun-Ying Wu, Ming-Shiang Wu, Cheng-Tang Chiu, Chun-Che Lin, Ping-I Hsu, Hsiu-Chi Cheng, Teng-Yu Lee, Hsiu-Po Wang, Jaw-Town Lin, Bor-Shyang Sheu, Chun-Ying Wu, Ming-Shiang Wu, Cheng-Tang Chiu, Chun-Che Lin, Ping-I Hsu, Hsiu-Chi Cheng, Teng-Yu Lee, Hsiu-Po Wang, Jaw-Town Lin

Abstract

Background and aims: To compose upper gastrointestinal bleeding (UGIB) consensus from a nationwide scale to improve the control of UGIB, especially for the high-risk comorbidity group.

Methods: The steering committee defined the consensus scope to cover preendoscopy, endoscopy, postendoscopy, and overview from Taiwan National Health Insurance Research Database (NHIRD) assessments for UGIB. The expert group comprised thirty-two Taiwan experts of UGIB to conduct the consensus conference by a modified Delphi process through two separate iterations to modify the draft statements and to vote anonymously to reach consensus with an agreement ≥80% for each statement and to set the recommendation grade.

Results: The consensus included 17 statements to highlight that patients with comorbidities, including liver cirrhosis, end-stage renal disease, probable chronic obstructive pulmonary disease, and diabetes, are at high risk of peptic ulcer bleeding and rebleeding. Special considerations are recommended for such risky patients, including raising hematocrit to 30% in uremia or acute myocardial infarction, aggressive acid secretory control in high Rockall scores, monitoring delayed rebleeding in uremia or cirrhosis, considering cycloxygenase-2 inhibitors plus PPI for pain control, and early resumption of antiplatelets plus PPI in coronary artery disease or stroke.

Conclusions: The consensus comprises recommendations to improve care of UGIB, especially for high-risk comorbidities.

References

    1. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Annals of Internal Medicine. 2010;152(2):101–113.
    1. Sung JJY, Chan FKL, Chen M, et al. Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut. 2011;60(9):1170–1177.
    1. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. The American Journal of Gastroenterology. 2004;99(7):1238–1246.
    1. Bensoussan K, Fallone CA, Barkun AN, et al. A sampling of Canadian practices in managing nonvariceal upper gastrointestinal bleeding before recent guideline publication: is there room for improvement? Canadian Journal of Gastroenterology. 2005;19(8):487–495.
    1. Lau JYW, Barkun A, Fan D, Kuipers EJ, Yang Y, Chan FKL. Challenges in the management of acute peptic ulcer bleeding. The Lancet. 2013;381(9882):2033–2043.
    1. Chow DKL, Sung JJY. Non-NSAID non-H. pylori ulcer disease. Best Practice and Research: Clinical Gastroenterology. 2009;23(1):3–9.
    1. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 1. Oxford Centre for Evidence-Based Medicine; 2014. .
    1. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. The New England Journal of Medicine. 2013;368(1):11–21.
    1. Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nature Clinical Practice Nephrology. 2007;3(3):138–153.
    1. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. New England Journal of Medicine. 2001;345(17):1230–1236.
    1. Livio M, Gotti E, Marchesi D, Mecca G, Remuzzi G, de Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell tranfusions. The Lancet. 1982;2(8306):1013–1015.
    1. Rockall TA, Logan RFA, Devlin HB, Northfield TC. Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage. National Audit of Acute Upper Gastrointestinal Haemorrhage. The Lancet. 1996;347(9009):1138–1140.
    1. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. The Lancet. 2000;356(9238):1318–1321.
    1. Wang CH, Chen YW, Young YR, Yang CJ, Chen IC. A prospective comparison of 3 scoring systems in upper gastrointestinal bleeding. The American Journal of Emergency Medicine. 2013;31(5):775–778.
    1. Lo AO, Lau JY. Gastrointestinal bleeding. Endoscopy. 2014;46:310–313.
    1. Lau JY, Leung WK, Wu JCY, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. The New England Journal of Medicine. 2007;356(16):1631–1640.
    1. Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (review) Cochrane Database of Systematic Reviews. 2010;7CD005415
    1. Lin HJ, Wang K, Perng CL, et al. Early or delayed endoscopy for patients with peptic ulcer bleeding: a prospective randomized study. Journal of Clinical Gastroenterology. 1996;22(4):267–271.
    1. Tai CM, Huang SP, Wang HP, et al. High-risk ED patients with nonvariceal upper gastrointestinal hemorrhage undergoing emergency or urgent endoscopy: a retrospective analysis. The American Journal of Emergency Medicine. 2007;25(3):273–278.
    1. Forrest JAH, Finlayson NDC, Shearman DJC. Endoscopy in gastrointestinal bleeding. The Lancet. 1974;2(7877):394–397.
    1. Laine L, Peterson WL. Bleeding peptic ulcer. The New England Journal of Medicine. 1994;331(11):717–727.
    1. Calvet X, Vergara M, Brullet E, Gisbert JP, Campo R. Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers. Gastroenterology. 2004;126(2):441–450.
    1. Marmo R, Rotondano G, Piscopo R, Bianco MA, D’Angella R, Cipolletta L. Dual therapy versus monotherapy in the endoscopic treatment of high-risk bleeding ulcers: a meta-analysis of controlled trials. The American Journal of Gastroenterology. 2007;102(2):279–289.
    1. Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clinical Gastroenterology and Hepatology. 2009;7(1):33–47.
    1. Barkun AN, Martel M, Toubouti Y, Rahme E, Bardou M. Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of meta-analyses. Gastrointestinal Endoscopy. 2009;69(4):786–799.
    1. Yang C-C, Shin J-S, Lin X-Z, Hsu P-I, Chen K-W, Lin C-Y. The natural history (fading time) of stigmata of recent hemorrhage in peptic ulcer disease. Gastrointestinal Endoscopy. 1994;40(5):562–566.
    1. Hsu P, Lin X, Chan S, et al. Bleeding peptic ulcer—risk factors for rebleeding and sequential changes in endoscopic findings. Gut. 1994;35(6):746–749.
    1. Hsu PI, Lai KH, Lin XZ, et al. When to discharge patients with bleeding peptic ulcers: a prospective study of residual risk of rebleeding. Gastrointestinal Endoscopy. 1996;44(4):382–387.
    1. Kahi CJ, Jensen DM, Sung JJY, et al. Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Gastroenterology. 2005;129(3):855–862.
    1. Lo CC, Hsu PI, Lo GH, et al. Comparison of hemostatic efficacy for epinephrine injection alone and injection combined with hemoclip therapy in treating high-risk bleeding ulcers. Gastrointestinal Endoscopy. 2006;63(6):767–773.
    1. Lin H, Lo W, Lee F, Perng C, Tseng G. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Archives of Internal Medicine. 1998;158(1):54–58.
    1. Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding. Annals of Internal Medicine. 2009;150(7):455–464.
    1. Wang C, Ma MH, Chou H, et al. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Archives of Internal Medicine. 2010;170(9):751–758.
    1. Chen C-C, Lee J-Y, Fang Y-J, et al. Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers. Alimentary Pharmacology and Therapeutics. 2012;35(8):894–903.
    1. Neumann I, Letelier LM, Rada G, et al. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database of Systematic Reviews. 2013;6CD007999
    1. Yen H, Yang C, Su W, Soon M, Wu S, Lin H. Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. BMC Gastroenterology. 2012;12, article 66
    1. Sung JJ, Suen BY, Wu JC, Lau JY, Ching JY, Lee VW. Effects of intravenous and oral esomeprazole in the prevention of recurrent bleeding from peptic ulcers after endoscopic therapy. The American Journal of Gastroenterology. 2014;109(7):1005–1010.
    1. Chan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology. 2004;127(4):1038–1043.
    1. Chan FKL, Wong VWS, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. The Lancet. 2007;369(9573):1621–1626.
    1. Liu NJ, Lee CS, Tang JH, et al. Outcomes of bleeding peptic ulcers: a prospective study. Journal of Gastroenterology and Hepatology. 2008;23(8):e340–e347.
    1. Zaragoza AM, Tenías JM, Llorente MJ, Alborch A. Prognostic factors in gastrointestinal bleeding due to peptic ulcer: construction of a predictive model. Journal of Clinical Gastroenterology. 2008;42(7):786–790.
    1. Tseng G-Y, Fang C-T, Lin H-J, et al. Efficacy of an intravenous proton pump inhibitor after endoscopic therapy with epinephrine injection for peptic ulcer bleeding in patients with uraemia: a case-control study. Alimentary Pharmacology and Therapeutics. 2009;30(4):406–413.
    1. Lin S-C, Wu K-L, Chiu K-W, et al. Risk factors influencing the outcome of peptic ulcer bleeding in end stage renal diseases after initial endoscopic haemostasis. International Journal of Clinical Practice. 2012;66(8):774–781.
    1. Chen L, Lin H, Hwang S, Lee F, Hou M, Lee S. Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension. Journal of Gastroenterology and Hepatology. 1996;11(1):59–64.
    1. Cheng HC, Kao AW, Chuang CH, Sheu BS. The efficacy of high- and low-dose intravenous omeprazole in preventing rebleeding for patients with bleeding peptic ulcers and comorbid illnesses. Digestive Diseases and Sciences. 2005;50(7):1194–1201.
    1. Cheng H, Chuang S, Kao Y, Kao A, Chuang C, Sheu B. Increased risk of rebleeding of peptic ulcer bleeding in patients with comorbid illness receiving omeprazole infusion. Hepato-Gastroenterology. 2003;50(54):2270–2273.
    1. Cheng HC, Chang WL, Yeh YC, Chen WY, Tsai YC, Sheu BS. Seven-day intravenous low-dose omeprazole infusion reduces peptic ulcer rebleeding for patients with comorbidities. Gastrointestinal Endoscopy. 2009;70(3):433–439.
    1. Cheng HC, Wu CT, Chang WL, Cheng WC, Chen WY, Sheu BS. Double oral esomeprazole after a 3-day intravenous esomeprazole infusion reduces recurrent peptic ulcer bleeding in high-risk patients: a randomised controlled study. Gut. 2014
    1. Komatsu T, Tamai Y, Takami H, Yamagata K, Fukuda S, Munakata A. Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic procedures. Journal of Gastroenterology. 2005;40(7):698–707.
    1. Sung JJY, Lau JYW, Ching JYL, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Annals of Internal Medicine. 2010;152(1):1–9.
    1. Hsu P. New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment. Journal of Gastroenterology and Hepatology. 2012;27(4):654–661.
    1. Liu CP, Chen WC, Lai KH, et al. Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. American Journal of Gastroenterology. 2012;107(7):1022–1029.
    1. Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clinical Gastroenterology and Hepatology. 2006;4(7):860–865.
    1. Hsu PI, Lai KH, Liu CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 2011;140(3):791–798.
    1. Chan FKL, Ching JYL, Hung LCT. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ucler bleeding. The New England Journal of Medicine. 2005;352(3):317–319.
    1. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. The New England Journal of Medicine. 2010;363(20):1909–1917.
    1. Tsoi KKF, Chan HCH, Chiu PWY, Pau CYY, Lau JYW, Sung JJY. Second-look endoscopy with thermal coagulation or injections for peptic ulcer bleeding: a meta-analysis. Journal of Gastroenterology and Hepatology. 2010;25(1):8–13.
    1. Ouali SE, Barkun AN, Wyse J, et al. Is routine second-look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding? A meta-analysis. Gastrointestinal Endoscopy. 2012;76(2):283–292.
    1. Luo J-C, Leu H-B, Hou M-C, et al. Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study. Alimentary Pharmacology and Therapeutics. 2012;36(6):542–550.
    1. Kuo CC, Kuo HW, Lee IM, Lee CT, Yang CY. The risk of upper gastrointestinal bleeding in patients treated with hemodialysis: a population-based cohort study. BMC Nephrology. 2013;14, article 15
    1. Luo J, Leu H, Huang K, et al. Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. Canadian Medical Association Journal. 2011;183(18):E1345–E1351.
    1. Peng YL, Leu HB, Luo JC, et al. Diabetes is an independent risk factor for peptic ulcer bleeding: a nationwide population-based cohort study. Journal of Gastroenterology and Hepatology. 2013;28(8):1295–1299.
    1. Huang KW, Luo JC, Leu HB, et al. Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study. Alimentary Pharmacology and Therapeutics. 2012;35(7):796–802.
    1. Wu C, Wu M, Kuo KN, Wang C, Chen Y, Lin J. Long-term peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study. Gut. 2011;60(8):1038–1042.
    1. Hsu YC, Lin JT, Chen TT, Wu MS, Wu CY. Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: a 10-year nationwide cohort study. Hepatology. 2012;56(2):698–705.
    1. Chang CH, Chen HC, Lin JW, Kuo CW, Shau WY, Lai MS. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiology and Drug Safety. 2011;20(7):763–771.
    1. Lee Y, Chang C, Lin J, Chen H, Lin M, Lai M. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver International. 2012;32(5):859–866.
    1. Li N, Wallén NH, Ladjevardi M, Hjemdahl P. Effects of serotonin on platelet activation in whole blood. Blood Coagulation and Fibrinolysis. 1997;8(8):517–523.
    1. Lee YC, Shau WY, Chang CH, Chen ST, Lin MS, Lai MS. Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients: a nationwide cohort study in Taiwan. Journal of Clinical Psychopharmacology. 2012;32(4):518–524.
    1. Wu C, Wu M, Wang C, Cheng J, Kuo KN, Lin J. A nationwide population-based cohort study shows reduced hospitalization for peptic ulcer disease associated with H. pylori eradication and proton pump inhibitor use. Clinical Gastroenterology and Hepatology. 2009;7(4):427–431.
    1. Hsiao F, Tsai Y, Wen Y, Kuo KN, Tsai C, Huang W. Effect of Helicobacter pylori eradication therapy on risk of hospitalization for a major ulcer event. Pharmacotherapy. 2011;31(3):239–247.
    1. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gené E, Dominguez-Muñoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database of Systematic Reviews. 2004;(2)CD004062
    1. Wu C, Kuo KN, Wu M, Chen Y, Wang C, Lin J. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology. 2009;137(5):1641–1648.
    1. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China, a randomized controlled trial. The Journal of the American Medical Association. 2004;291(2):187–194.
    1. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Annals of Internal Medicine. 2009;151(2):121–128.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다